From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study
Timing of perioperative denosumab
No. of patients (%)
No. of institutions (%)
Preoperative only
21 (53%)
10 (63%)
Postoperative only
9 (23%)
5 (31%)
Both pre- and postoperative
10 (25%)
Total
40
16*